)
Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The Lancet 375(9724): 14471456 35
Researchers documented these milestones in uncovering the vision risks: Summer 2023: Three NAION cases presented at Mass Eye and Ear within a short period, all involving semaglutide users July 2024: Publication of the landmark Harvard study in JAMA Ophthalmology revealing increased NAION risk December 2024: Danish researchers published supporting studies involving over 424,000 patients 2025: Multiple international studies confirmed the association between semaglutide and vision problems The pivotal Harvard study analyzed medical records from 16,827 patients treated between 2017 and 2023, comparing those prescribed semaglutide against patients using other diabetes or weight loss medications
Roughly 38% of MassHealth enrollees have a BMI over 30, which translates to approximately 800,000 people who would be clinically eligible for Wegovy if obesity alone were a covered indication (Massachusetts Department of Public Health Obesity Data, 2025)
Because GLP-1 medications increase feelings of fullness, your usual portion sizes may suddenly feel too large
Medications such as Gaviscon double-action, Wind-Setler, containing dimeticone, and Alka-Seltzer, may provide relief for some individuals
Virtually every person with disease-related frailty is depleted in glutathione
